Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphom...

by Chu, Y., Awasthi, A., Lee, S., Edani, D., Yin, C., Hochberg, J., Shah, T., Chung, T.-H., Ayello, J., van de Ven, C., Klein, C., Lee, D., Cairo, M.S.
Published 2021